Publications by authors named "D McCarty"
Article Synopsis
- * Interviews were conducted with 12 mothers from low socioeconomic backgrounds, highlighting that barriers to maternal presence are largely societal and institutional, while facilitators depend on personal and interpersonal circumstances.
- * Recommendations for hospitals include offering free or low-cost sibling support, reducing parking fees, and providing clear communication about available resources to help families during their hospital stays.
Article Synopsis
- The study investigates how factors like race and socioeconomic status affect maternal presence in the Neonatal Intensive Care Unit (NICU), with a focus on mothers of Black infants.
- It finds that Medicaid status significantly predicts lower maternal presence rates, particularly among mothers with lower socioeconomic status.
- The authors suggest that interventions must target the resource-related challenges faced by low-SES mothers to improve their ability to be present in the NICU.
A long-standing policy prohibits the use of federal funds for Medicaid services in Institutions for Mental Diseases (facilities with more than sixteen beds that specialize in mental health or substance use disorder treatment). Beginning in 2015, states could apply for Section 1115 Medicaid waivers, which permit federal funding for Institutions for Mental Diseases services and require improvements in opioid use disorder (OUD) treatment. Using 2016-20 Medicaid data, we compared changes in the use of medications for OUD and nonfatal overdoses in seventeen states with waivers approved during 2017-19 to changes in eighteen states without waivers.
View Article and Find Full Text PDFEmerging legal frameworks in Oregon and Colorado license facilitators to support adults receiving psychedelic services. The current legal frameworks are silent regarding facilitators' personal experience with psychedelics. An e-Delphi process recruited 36 experts with at least 5 years' experience facilitating psilocybin experiences in ceremonial settings, indigenous practices, or clinical trials.
View Article and Find Full Text PDFIntroduction: At the beginning of the COVID-19 pandemic, federal agencies permitted telehealth initiation of buprenorphine treatment for opioid use disorder (OUD) without in-person assessment. It remains unclear how telehealth-only buprenorphine treatment impacts time to discontinuation and patient reported treatment outcomes.
Methods: A longitudinal observational cohort study conducted September 2021 through March, 2023 enrolled participants with OUD initiating buprenorphine (≤ 45 days) with internet and phone access in Oregon and Washington.